<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03518047</url>
  </required_header>
  <id_info>
    <org_study_id>M16-176</org_study_id>
    <nct_id>NCT03518047</nct_id>
  </id_info>
  <brief_title>Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation</brief_title>
  <acronym>IMMPRESS</acronym>
  <official_title>rIsankizuMab Versus Placebo in a Randomized, Double Blind, Parallel Group Trial in Moderate to Severe Plaque psoRiasis to assESS Safety and Efficacy After 16 Weeks of Treatment in the Russian Federation (IMMpress)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of risankizumab compared to
      placebo in subjects with moderate to severe chronic plaque psoriasis in the Russian
      Federation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 13, 2018</start_date>
  <completion_date type="Anticipated">February 7, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with a 90% reduction from Baseline Psoriasis Area and Severity Index (PASI 90) at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The PASI score is an established measure of clinical efficacy for psoriasis medications.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with Static Physician Global Assessment (sPGA) score of clear or almost clear (0, 1) at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The sPGA is based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a 75% reduction from Baseline Psoriasis Area and Severity Index (PASI 75) at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The PASI score is an established measure of clinical efficacy for psoriasis medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a 100% reduction from Baseline Psoriasis Area and Severity Index (PASI 100) at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The PASI score is an established measure of clinical efficacy for psoriasis medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The DLQI is a self-administered, ten-question questionnaire used to assess the effect of different skin diseases on a subject's quality of life, overall health, and disability status. Scores range from 0 (not relevant/not at all) to 3 (very much).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for risankizumab by subcutaneous (SC) injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risankizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Risankizumab by subcutaneous (SC) injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risankizumab</intervention_name>
    <description>rizankizumab subcutaneous (SC) infusion</description>
    <arm_group_label>Risankizumab</arm_group_label>
    <other_name>ABBV-066</other_name>
    <other_name>BI 655066</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo for rizankizumab</intervention_name>
    <description>placebo for rizankizumab subcutaneous (SC) infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) for at
             least 6 months before the first administration of study drug.

          -  moderate to severe chronic plaque psoriasis at both Screening and Baseline
             (Randomization) Visits

          -  candidates for systemic therapy or phototherapy for psoriasis treatment as assessed by
             the investigator

        Exclusion Criteria:

          -  Prior therapy with an anti-interleukin (IL)-17 or anti-IL12/23p40 or anti-IL-23p19
             inhibitor

          -  Concurrent therapy with a biologic and/or other systemic therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>GBUZ Interdisctrict Multidisciplinary Hospital</name>
      <address>
        <city>Anzorey</city>
        <state>Kabardino-Balkarskaya Respublika</state>
        <zip>361350</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>GBUZ Clinical Dermatovenerology Dispensary of MoH of Krasnodar region</name>
      <address>
        <city>Krasnodar</city>
        <state>Krasnodarskiy Kray</state>
        <zip>350020</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>FSBIH ''Siberian District Medical Centre of FMBA of Russia''</name>
      <address>
        <city>Novosibirsk</city>
        <state>Novosibirskaya Oblast</state>
        <zip>630007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>SBHI KVD # 10 Clinic of Dermatology and venerology</name>
      <address>
        <city>Saint-Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>194021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>LLC ArsVitae Severo-Zapad</name>
      <address>
        <city>Saint-Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>194223</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>LLC Kurator</name>
      <address>
        <city>Saint-Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>196240</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #7</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan, Respublika</state>
        <zip>420103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alliance Biomedical Ural Group</name>
      <address>
        <city>Izhevsk</city>
        <zip>426035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2018</study_first_submitted>
  <study_first_submitted_qc>May 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2018</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plaque Psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

